Dimpal M. Kasabwala

Ms. Dimpal M. Kasabwala

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 November 2022 in Biomedicines
Verified
Journal Article
Open access
PDF file
DKDimpal M. Kasabwala
Dimpal M. Kasabwala
RBRaymond Bergan
Raymond Bergan
KGKirby Patrick Gardner
Kirby Patrick Gardner
RLRena Lapidus
Rena Lapidus
STSusan Tsai
Susan Tsai
DADaniel L Adams
Daniel L Adams
Micronuclei (MN) are fragments of damaged nucleic acids which budded from a cell’s nuclei as a repair mechanism for chromosomal instabilities, which within circulating white blood cells (cWBCs) signifies increased cancer risk, and in tumor cells indicates aggressive subtypes. MN form overtime and with therapy induction, which requires sequential monitoring of rarer cell subpopulations. We evaluated the peripheral blood (7.5 mL) for MN in Circulating Stromal Cells (CStCs) in a prospective pilot study of advanced colorectal cancer patients (n = 25), identifying MN by DAPI+ structures (<3 µm) within the cellular cytoplasm. MN+ was compared to genotoxic induction, progression free survival (PFS) or overall survival (OS) hazard ratios (HR) over three years. MN were identified in 44% (n = 11/25) of CStCs, but were not associated with genotoxic therapies (p = 0.110) nor stage (p = 0.137). However, presence of MN in CStCs was independently prognostic for PFS (HR = 17.2, 95% CI 3.6–80.9, p = 0.001) and OS (HR = 70.3, 95% CI 6.6–752.8, p = 0.002), indicating a non-interventional mechanism in their formation. Additionally, MN formation did not appear associated with chemotherapy induction, but was correlated with tumor response. MN formation in colorectal cancer is an underlying biological mechanism that appears independent of chemotherapeutic genotoxins, changes during treatment, and predicts for poor clinical outcomes.

30 October 2026 in Journal of Surgical Research
Verified
Journal Article
Closed access
YOYusra Othman
Yusra Othman
DKDimpal M. Kasabwala
Dimpal M. Kasabwala
KJKeshavkiran Jayagopi
Keshavkiran Jayagopi
AKAlexandra Kata
Alexandra Kata
IBIan Bundschu
Ian Bundschu
AEAdel Elkbuli
Adel Elkbuli

29 December 2022 in Research Square
Verified
Preprint
Open access
PDF file
AAAmama Ali
Amama Ali
DADaniel L. Adams
Daniel L. Adams
DKDimpal M. Kasabwala
Dimpal M. Kasabwala
CTCha-Mei Tang
Cha-Mei Tang
THThai H. Ho
Thai H. Ho
Background Renal Cell Carcinoma (RCC) is a fatal urological cancer, with one third of patients diagnosed with metastasis, resulting in a 5-year survival of only 12%. Recent advancements in therapies have increased survival in mRCC, but lack efficacy in subtypes, due to treatment resistance and toxic side effects. Currently, white blood cells, hemoglobin, and platelets are limitedly used as blood based biomarkers to help determine RCC prognosis. Cancer associated macrophage-like cells (CAMLs) area potential mRCC biomarker which have been identified in peripheral blood of patients with malignant tumors and have been shown to predict poor clinical patient outcomes based on their number and size. Methods In this study, blood samples from 40 RCC patients were obtained to evaluate the clinical utility of CAMLs. CAML changes were monitored during treatment regimens to evaluate their ability to predict treatment efficacy. Results It was observed that patients with smaller CAMLs had better progression free survival (HR=2.84, 95%CI 1.22-6.60, p=0.0273) and overall survival (HR=3.95, 95%CI 1.45-10.78, p=0.0154) versus patients with larger CAMLs. Conclusion These findings suggest that CAMLs can be used as a diagnostic, prognostic, and predictive biomarker for patients with RCC which may help improve management of advanced RCC.

28 October 2026 in Injury
Verified
Journal Article
Closed access
YOYusra Othman
Yusra Othman
DKDimpal M. Kasabwala
Dimpal M. Kasabwala
KJKeshavkiran Jayagopi
Keshavkiran Jayagopi
JLJuliette Lemoine
Juliette Lemoine
DPDaniel Park
Daniel Park
AEAdel Elkbuli
Adel Elkbuli